Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer

Clinical trial NCT07261683 · RECRUITING

Trial details

NCT number: NCT07261683
Sponsor: Obstetrics & Gynecology Hospital of Fudan University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Ovarian Cancer Immunotherapy Pembrolizumab

Start date: 2025-12-01
Primary completion: 2027-11-30
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.